<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02493959</url>
  </required_header>
  <id_info>
    <org_study_id>STKBM-PI14</org_study_id>
    <nct_id>NCT02493959</nct_id>
  </id_info>
  <brief_title>Degradation of the Anorexic Hormone Peptide YY</brief_title>
  <official_title>Degradation of the Anorexic Hormone Peptide YY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peptide YY (PYY) is a gastrointestinal hormone released from the enteroendocrine cell upon
      food intake. The N-terminal truncated form, PYY3-36, exerts anorexic effects. In this study
      we want to investigate the kinetics of PYY1-36 and PYY3-36 and to examine whether a
      C-terminally degraded metabolite, PYY3-34, is formed after infusion of PYY.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PYY3-34 concentration</measure>
    <time_frame>0-240 min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-lives of PYY1-36 and PYY3-36</measure>
    <time_frame>0-240 min</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Appetite and nausea scores</measure>
    <time_frame>0-240 min</time_frame>
    <description>Between infusion differences in VAS scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>0-240 min</time_frame>
    <description>Between infusion differences in blood pressure</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood glucose</measure>
    <time_frame>0-240 min</time_frame>
    <description>Between infusion differences in blood glucose</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>0-240 min</time_frame>
    <description>Between infusion differences in heart rate</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PYY infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PYY1-36 infusion</intervention_name>
    <description>Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.</description>
    <arm_group_label>PYY infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PYY1-36 + sitagliptin</intervention_name>
    <description>Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.</description>
    <arm_group_label>PYY infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PYY3-36 infusion</intervention_name>
    <description>0.8 pmol/kg/min infusion of PYY3-36.</description>
    <arm_group_label>PYY infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Infusion of saline for 2 hrs.</description>
    <arm_group_label>PYY infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Normal BMI (18.5-25kg/m2)

        Exclusion Criteria:

          -  Diabetes Mellitus

          -  Gastric bypass

          -  Non-caucasian

          -  Height changes &gt;3 kg within last two months

          -  Hemoglobin &lt; 7.6 mmol/l

          -  Chronic disease

          -  Smoking

          -  Regularly use of medicine

          -  Drug abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Endocrinology, Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Kirstine Nyvold Bojsen-Moeller</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>PYY</keyword>
  <keyword>Degradation</keyword>
  <keyword>kinetics</keyword>
  <keyword>men</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

